Literature DB >> 86267

Hormone blood levels and their inter-relationships in normal men and men with benign prostatic hyperplasia (BPH).

W Bartsch, H Becker, F A Pinkenburg, M Krieg.   

Abstract

In 128 non-hospitalized men (age range 36-65 years) rectal palpation revealed in 54 cases an enlargement of the prostate (group II), which was very distinct in 20 cases (group III). The measurement of testosterone (T), 5alpha-dihydrotestosterone (DHT), 5alpha-androstane-3alpha,17beta-diol (3alpha-diol) oestradiol (Oe2), sex-hormone-binding-globulin binding capacity (SHBG), luteinizing hormone (LH), follicle stimulating hormone (FSH) and prolactin (Prl) in the blood of normal men (group I) and those with BPH (group II or III) demonstrated no significant differences between the three groups when respective age ranges were compared. A significant increase of FSH and decrease of 3alpha-diol with age was seen in the normal group (I), which was similar but less pronounced in BPH (groups II and III). A distinct increase of DHT with age was found in BPH (group II), which was not so dominant in normal men (group I). From these data it is concluded that the conversion of DHT to 3alpha-diol might be reduced in older males independent from the occurrence of BPH and that the hyperplastic prostate possibly secretes significant amounts of DHT into the circulation. These results are discussed with respect to their possible role in the pathogenesis of BPH.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 86267     DOI: 10.1530/acta.0.0900727

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  7 in total

1.  Observations with Bazoton in the management of prostatic hyperplasia.

Authors:  I Romics
Journal:  Int Urol Nephrol       Date:  1987       Impact factor: 2.370

2.  Circulating testosterone, prostatic nuclear androgen receptor and time to progression in patients with metastatic disease of the prostate treated by orchiectomy.

Authors:  O G van Aubel; J Bolt-de Vries; M A Blankenstein; F H de Jong; F H Schröder
Journal:  Urol Res       Date:  1989

Review 3.  Age-related changes in male gonadal function. Implications for therapy.

Authors:  D Maas; A Jochen; B Lalande
Journal:  Drugs Aging       Date:  1997-07       Impact factor: 3.923

4.  Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial.

Authors:  Alan R Kristal; Jeannette M Schenk; YoonJu Song; Kathryn B Arnold; Marian L Neuhouser; Phyllis J Goodman; Daniel W Lin; Frank Z Stanczyk; Ian M Thompson
Journal:  Am J Epidemiol       Date:  2008-10-21       Impact factor: 4.897

Review 5.  Benign prostatic hyperplasia. Current pharmacological treatment.

Authors:  M Jønler; M Riehmann; R C Bruskewitz
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

6.  Studies on the role of the sex-hormone-binding globulin (SHBG) in prostatic gland hypertrophy in men. II. In vitro research.

Authors:  A Pachman
Journal:  Int Urol Nephrol       Date:  1984       Impact factor: 2.370

7.  Studies on the role of sex-hormone-binding globulin (SHBG) in benign prostatic hypertrophy in men. I. Clinical research.

Authors:  A Pachman
Journal:  Int Urol Nephrol       Date:  1984       Impact factor: 2.370

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.